Phost'in Therapeutics

Executive Summary

Phost'in Therapeutics is a French biotech pioneering Glyco-Immuno-Oncology with first-in-class glycocalyx modifiers that target aberrant N-glycosylation, a key immune evasion mechanism in tumors. Its lead oral candidate, PhOx430, is a GnT-V inhibitor designed to restore immune activity and reduce tumor invasiveness. Currently in Phase 1/2 trials, PhOx430 has the potential to address multiple solid tumors by unblocking the immune system. The company's approach is highly differentiated, addressing a novel biology (glycosylation) that is underexplored in oncology. If successful, PhOx430 could complement or replace existing immunotherapies. However, the early clinical stage and lack of disclosed financials introduce risk. Phost'in's position as a private company with limited public data makes conviction moderate, but the scientific rationale and unmet need support upside potential.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim safety and efficacy data for PhOx43060% success
• Q3 2026Series A or B financing round to advance clinical development70% success
• Q2 2026Regulatory update or orphan drug designation from EMA or FDA50% success